Compare IDEXX Laboratories, Inc. (IDXX) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Las Vegas Sands Corp. — how do they compare? IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B), while Las Vegas Sands Corp. trades at $40.57 (market cap $30.13B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.42% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LVS | |
|---|---|---|
Market Cap | $43.58B | $30.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $69.49 |
52-Week Low | $526.44 | $44.78 |
Enterprise Value | $44.48B | $42.52B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
LVS trades at $45.47, showing modest 0.24% daily gains amid bearish technical signals. The company demonstrates strong fundamental performance with consistent earnings beats, including Q1 2026 EPS of $0.91 exceeding expectations by 20%. Revenue growth accelerated to $13.02B in 2025, while maintaining solid profitability with 13.41% net margins. Recent corporate actions include a $0.30 dividend payment and $740M share repurchases in Q1 2026.
Analyst consensus remains strongly bullish with 61% buy ratings and $64.75 price target representing 42% upside. Key risks include high debt levels at 73.15% debt-to-asset ratio and potential regulatory headwinds in gaming markets. The combination of strong earnings momentum, attractive valuation at 16.9 P/E, and positive institutional sentiment supports a constructive outlook despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
